pCW57-RFP-P2A-MCS Citations (10)

Originally described in: Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer.
Barger CJ, Branick C, Chee L, Karpf AR Cancers (Basel). 2019 Feb 21;11(2). pii: cancers11020251. doi: 10.3390/cancers11020251. PubMed Journal

---

Articles Citing pCW57-RFP-P2A-MCS

Articles
MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer. Augert A, Mathsyaraja H, Ibrahim AH, Freie B, Geuenich MJ, Cheng PF, Alibeckoff SP, Wu N, Hiatt JB, Basom R, Gazdar A, Sullivan LB, Eisenman RN, MacPherson D. Cancer Cell. 2020 Jul 13;38(1):97-114.e7. doi: 10.1016/j.ccell.2020.04.016. Epub 2020 May 28. PubMed
Establishment of a Reverse Genetic System from a Bovine Derived Influenza D Virus Isolate. Holwerda M, Laloli L, Wider M, Schonecker L, Becker J, Meylan M, Dijkman R. Viruses. 2021 Mar 18;13(3). pii: v13030502. doi: 10.3390/v13030502. PubMed
G3BP1 inhibits Cul3(SPOP) to amplify AR signaling and promote prostate cancer. Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LD, Cyrta J, Davicioni E, Sboner A, Robinson BD, Chinnaiyan AM, Rubin MA, Barbieri CE, Zhou P. Nat Commun. 2021 Nov 18;12(1):6662. doi: 10.1038/s41467-021-27024-x. PubMed
The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability. Ravn-Boess N, Roy N, Hattori T, Bready D, Donaldson H, Lawson C, Lapierre C, Korman A, Rodrick T, Liu E, Frenster JD, Stephan G, Wilcox J, Corrado AD, Cai J, Ronnen R, Wang S, Haddock S, Sabio Ortiz J, Mishkit O, Khodadadi-Jamayran A, Tsirigos A, Fenyo D, Zagzag D, Drube J, Hoffmann C, Perna F, Jones DR, Possemato R, Koide A, Koide S, Park CY, Placantonakis DG. Cell Rep. 2023 Nov 28;42(11):113374. doi: 10.1016/j.celrep.2023.113374. Epub 2023 Nov 8. PubMed
Rapid binding to protofilament edge sites facilitates tip tracking of EB1 at growing microtubule plus-ends. Gonzalez SJ, Heckel JM, Goldblum RR, Reid TA, McClellan M, Gardner MK. Elife. 2024 Feb 22;13:e91719. doi: 10.7554/eLife.91719. PubMed
Nek2A prevents centrosome clustering and induces cell death in cancer cells via KIF2C interaction. Kalkan BM, Ozcan SC, Cicek E, Gonen M, Acilan C. Cell Death Dis. 2024 Mar 16;15(3):222. doi: 10.1038/s41419-024-06601-0. PubMed
Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. Zhang Y, Fong KW, Mao F, Wang R, Allison DB, Napier D, He D, Liu J, Zhang Y, Chen J, Kong Y, Li C, Li G, Liu J, Li Z, Zhu H, Wang C, Liu X. Cell Rep. 2024 Jul 23;43(7):114431. doi: 10.1016/j.celrep.2024.114431. Epub 2024 Jul 4. PubMed
MAX inactivation deregulates the MYC network and induces neuroendocrine neoplasia in multiple tissues. Freie B, Ibrahim AH, Carroll PA, Bronson RT, Augert A, MacPherson D, Eisenman RN. Sci Adv. 2025 Apr 25;11(17):eadt3177. doi: 10.1126/sciadv.adt3177. Epub 2025 Apr 25. PubMed
A Novel Chemotherapy Combination to Enhance Proteotoxic Cell Death in Hepatocellular Carcinoma Experimental Models Without Killing Non-Cancer Cells. Perez-Stable C, de Las Pozas A, Reiner T, Gomez J, Nagarajan M, Foster RT, Ure DR, Wangpaichitr M. Int J Mol Sci. 2025 Jul 12;26(14):6699. doi: 10.3390/ijms26146699. PubMed
Cyclophilin Inhibitor Rencofilstat Combined with Proteasome Inhibitor Ixazomib Increases Proteotoxic Cell Death in Advanced Prostate Cancer Cells with Minimal Effects on Non-Cancer Cells. Perez-Stable C, de Las Pozas A, Wangpaichitr M, Foster RT, Ure DR. Biomedicines. 2025 Oct 7;13(10):2442. doi: 10.3390/biomedicines13102442. PubMed

If you have published an article using this material, please email us at to have your article added to this page.